The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

August 31, 2018

Conditions
GERD Gastroesophageal Reflux Disease
Interventions
DRUG

Omeprazole

DEVICE

LINX Reflux Management System

Trial Locations (21)

15213

University of Pittsburgh Medical Center, Pittsburgh

19141

Albert Einstein Healthcare Network, Philadelphia

30309

Esophageal Institute of Atlanta, PC., Atlanta

36617

University of South Alabama, Mobile

41017

St. Elizabeth Healthcare, Edgewood

44106

University Hospitals Cleveland Medical Center - Geauga, Cleveland

56441

Cuyuna Regional Medical Center, Crosby

78665

Scott and White Memorial Hospital, Round Rock

80110

SurgOne Foregut Institute, Englewood

Unknown

Bapist Health, Heber Springs

University of Southern California, Los Angeles

UCSD, San Diego

Albany Surgical PC, Albany

Anne Arundel Medical Center, Annapolis

Jersey Shore University Medical Center, Neptune City

Adirondack Surgical Group, LLC, Saranac Lake

Knox Community Hospital, Mount Vernon

The Oregon Clinic, Portland

Swedish Cancer Institute, Seattle

Gundersen Lutheran, La Crosse

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Torax Medical Incorporated

INDUSTRY

NCT02505945 - The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease | Biotech Hunter | Biotech Hunter